| Dermatitis, Atopic
Cibinqo vs Eucrisa
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Cibinqo vs Eucrisa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEucrisa has a higher rate of injection site reactions vs Cibinqo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eucrisa but not Cibinqo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cibinqo
Eucrisa
At A Glance
Oral
Once daily
JAK inhibitor
Topical
Twice daily
PDE-4 inhibitor
Indications
- Dermatitis, Atopic
- Dermatitis, Atopic
Dosing
Dermatitis, Atopic 100 mg orally once daily; may increase to 200 mg once daily for inadequate response. In moderate renal impairment or CYP2C19 poor metabolizers: 50 mg once daily, may increase to 100 mg once daily for inadequate response.
Dermatitis, Atopic Apply a thin layer twice daily to affected areas; once clinical effect is achieved, consider reducing to once daily. For topical use only.
Contraindications
- Patients taking antiplatelet therapies (except low-dose aspirin <=81 mg daily) during the first 3 months of treatment
- Known hypersensitivity to crisaborole or any component of the formulation
Adverse Reactions
Most common (>=1%) Nasopharyngitis (8.7-12.4%), nausea (6.0-14.5%), headache (6.0-7.8%), herpes simplex (3.3-4.2%), increased blood creatine phosphokinase (2.3-2.9%), dizziness (1.8-2.9%), urinary tract infection (1.7-2.2%), fatigue (1.3-1.6%), acne (1.6-4.7%), vomiting (1.5-3.2%), impetigo (0.5-1.5%), oropharyngeal pain (1.0-1.4%), hypertension (0.8-1.2%), influenza (1.1-1.2%), gastroenteritis (1.1-1.3%), dermatitis contact (0.5-1.1%), abdominal pain upper (0.6-1.9%), abdominal discomfort (0.5-1.2%), herpes zoster (0.3-1.2%), thrombocytopenia (0-1.5%)
Serious Serious infections including herpes simplex, herpes zoster, and pneumonia (2.3 per 100 patient-years); thrombosis including pulmonary embolism and deep vein thrombosis; major adverse cardiovascular events; malignancy; retinal detachment
Most common (>=1%) Application site pain
Postmarketing Allergic contact dermatitis
Pharmacology
Abrocitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits JAK1 by blocking the ATP binding site. It is selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and TYK2 (43-fold).
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor; PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels, though the specific mechanism by which it treats atopic dermatitis is not well defined.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cibinqo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Eucrisa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Cibinqo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Eucrisa
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Cibinqo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Eucrisa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Eucrisa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CibinqoView full Cibinqo profile
EucrisaView full Eucrisa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.